Valuation : AbbVie

Market Cap 465B 399B 373B 342B 644B 44,370B 646B 4,421B 1,728B 22,362B 1,744B 1,707B 74,011B P/E 2026 *
33.6x
P/E 2027 * 24.8x
Enterprise Value 525B 451B 422B 386B 728B 50,148B 730B 4,997B 1,953B 25,274B 1,971B 1,929B 83,647B EV / Sales 2026 *
7.77x
EV / Sales 2027 * 7.02x
Free-Float
95.71%
Yield 2026 *
2.61%
Yield 2027 * 2.74%
Manager TitleAgeSince
Chief Executive Officer 55 01/07/2024
Director of Finance/CFO 59 23/06/2022
Chief Tech/Sci/R&D Officer - 01/03/2024
Director TitleAgeSince
Director/Board Member 65 01/01/2013
Director/Board Member 74 01/01/2013
Director/Board Member 69 01/01/2013
Change 5-day change 1-year change 3-year change Capi.($)
-8.07%-3.48% - - 465B
-1.43%-5.15%+60.77%+113.09% 1,060B
-1.60%-0.58%+50.36%+61.80% 651B
-1.99%-1.56%+23.88%+74.82% 465B
-1.17%-2.10%+38.61%+40.46% 365B
-2.00%-1.35%+22.22%+37.78% 300B
-0.98%+0.53%+2.04%+12.13% 258B
-0.64%+0.95%+52.05%+70.67% 238B
-3.18%-0.30%-17.23%-54.33% 210B
+0.19%+3.53%+30.35%+92.76% 184B
Average -2.01%-0.66%+29.23%+49.91% 414.49B
Weighted average by Cap. -2.14%-2.16%+38.58%+66.09%

Financials

2026 *2027 *
Net sales 67.58B 58.01B 54.31B 49.73B 93.69B 6,455B 93.96B 643B 251B 3,253B 254B 248B 10,767B 73.52B 63.11B 59.08B 54.1B 102B 7,022B 102B 700B 274B 3,539B 276B 270B 11,712B
Net income 13.86B 11.9B 11.14B 10.2B 19.22B 1,324B 19.27B 132B 51.57B 667B 52.04B 50.92B 2,208B 18.91B 16.24B 15.2B 13.92B 26.22B 1,806B 26.29B 180B 70.36B 910B 71.01B 69.48B 3,013B
Net Debt 60.49B 51.92B 48.61B 44.51B 83.86B 5,777B 84.09B 576B 225B 2,912B 227B 222B 9,637B 51.66B 44.35B 41.52B 38.02B 71.62B 4,934B 71.82B 492B 192B 2,487B 194B 190B 8,230B
Logo AbbVie
AbbVie Inc. specializes in therapeutic drug research and development. Its products are intended for treating rheumatoid arthritis, psoriasis, Crohn's disease, thyroid disease, Parkinson's disease, HIV, complications of mucoviscidosis, low testosterone levels, and complications associated with chronic renal disease. Net sales are distributed geographically as follows: the United States (76.2%), Germany (2.8%), Japan (2.1%), Canada (2%), China (1.6%), France (1.3%), the United Kingdom (1%), Spain (1%), Italy (0.9%), Brazil (0.8%), Australia (0.8%), and Other (9.5%).
Employees
-
Trader
Investor
Global
Quality
ESG MSCI
AA